ClinicalTrials.Veeva

Menu

Gene Therapy for Tay-Sachs Disease

University of Minnesota (UMN) logo

University of Minnesota (UMN)

Status

Completed

Conditions

Tay Sachs Disease
Sandhoff Disease
Late Onset Tay Sachs Disease

Study type

Observational

Funder types

Other
NETWORK
NIH

Identifiers

NCT01869270
U54NS065768 (U.S. NIH Grant/Contract)
0905M66723

Details and patient eligibility

About

Hypothesis: To study the natural history of Tay-Sachs disease and evaluate therapeutic interventions.

This study is intended to work in collaboration with NCT00668187 "A Natural History Study of Hexosaminidase Deficiency." Because so few patients with Tay-Sachs disease present annually, we will maximize both research projects by enrolling patients in both studies. For this present study, we will perform retrospective medical record review to gather data. Through this medical record review, we will collect biomarker analysis results, neuroimaging report data, quality-of-life questionnaire data and ophthalmology exam findings. If the subject has undergone therapy or treatment, the results will be noted.

Full description

Much has been done in the past four decades to better understand, improve diagnostic measures of, and prevent hexosaminidase deficiency diseases, yet all of them - Tay-Sachs, Sandhoff, and Late Onset Tay-Sachs (LOTS) - remain diseases without treatment. Much work remains to be done to understand and effectively treat these diseases. To date, no comprehensive assessment of the natural history of Tay-Sachs or Sandhoff has been undertaken. The information that is gathered through this study will characterize and describe the Tay-Sachs disease population as a whole, including the variability and progression of this disease. This information, in turn, will function as a point of reference against which to assess the efficacy of therapeutic interventions. Therapeutic interventions may include any treatments/therapies the subject may have undergone in the past, including hematopoietic cell transplantation, and/or the administration of miglustat, acetylcysteine, or other pharmaceutical agents; and possible future gene therapies.

Enrollment

4 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Any person who has been diagnosed with a hexosaminidase deficiency disease can be included in this study.

Exclusion criteria

The only exclusion criteria is a desire not to participate in this study.

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems